SCHEMBL4427205

SCHEMBL4427205

COc1ccccc1NC(=O)C[C@@H]1C(=O)Nc2ccccc2N1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 5/20 0.78
ALDH1A1 P00352 4/20 0.74
POLB P06746 2/20 0.74
MAPT P10636 3/20 0.62
MAPK1 P28482 1/20 0.62
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 2/20 0.53
MEN1 O00255 2/20 0.53
LMNA P02545 1/20 0.53
GLA P06280 1/20 0.53
TSHR P16473 1/20 0.53
GAA P10253 1/20 0.45
HSD17B10 Q99714 2/20 0.44
HTT P42858 1/20 0.44
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAP2K1 Q02750 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404693 1.00 BDKRB1 (0.78) BDKRB1ALDH1A1POLBMAPTMAPK1
SCHEMBL4421013 0.91 ALDH1A1 (0.71) BDKRB1ALDH1A1POLBMAPTMAPK1
SCHEMBL6408196 0.91 ALDH1A1 (0.71) BDKRB1ALDH1A1POLBMAPTMAPK1
SCHEMBL6402615 0.88 BDKRB1 (1.00) BDKRB1ALDH1A1POLBMAPTMAPK1
SCHEMBL6029674 0.85 ALDH1A1 (1.00) BDKRB1ALDH1A1POLBMAPTKMT2A
SCHEMBL6403536 0.85 ALDH1A1 (1.00) BDKRB1ALDH1A1POLBMAPTKMT2A
SCHEMBL15599334 0.81 ALDH1A1 (0.77) BDKRB1ALDH1A1POLBKMT2AGAA
SCHEMBL4424964 0.80 ALDH1A1 (0.76) BDKRB1ALDH1A1POLBMAPTKMT2A
SCHEMBL6407081 0.78 ALDH1A1 (0.86) BDKRB1ALDH1A1POLBMAPTMAPK1
SCHEMBL22563749 0.78 ALDH1A1 (0.77) BDKRB1ALDH1A1POLBMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US claimed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US claimed
US-7635775-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7183281-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2007-02-27 US disclosed
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2006-12-28 US disclosed
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK BDKRB1 2/4885ALDH1A1 3104/4885POLB 4615/4885
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists BDKRB2, BDKRB1, HRH2 BDKRB1 2/4885ALDH1A1 2364/4885POLB 4694/4885
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK BDKRB1 2/4885ALDH1A1 2366/4885POLB 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.